CN105902507A - 一种乙磺酸尼达尼布制剂及其应用 - Google Patents
一种乙磺酸尼达尼布制剂及其应用 Download PDFInfo
- Publication number
- CN105902507A CN105902507A CN201610406068.9A CN201610406068A CN105902507A CN 105902507 A CN105902507 A CN 105902507A CN 201610406068 A CN201610406068 A CN 201610406068A CN 105902507 A CN105902507 A CN 105902507A
- Authority
- CN
- China
- Prior art keywords
- sulfonic acid
- nintedanib
- ethyl sulfonic
- acid nintedanib
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004378 nintedanib Drugs 0.000 title claims abstract description 53
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title abstract description 11
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000008101 lactose Substances 0.000 claims abstract description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 7
- 229960001375 lactose Drugs 0.000 claims abstract 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 22
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 18
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 241001289435 Astragalus brachycalyx Species 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 235000002917 Fraxinus ornus Nutrition 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 235000001727 glucose Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- -1 fluidizer Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZNMRDZZRAFJOKY-UHFFFAOYSA-N ethanesulfonic acid methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate Chemical compound CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O ZNMRDZZRAFJOKY-UHFFFAOYSA-N 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960003129 nintedanib esylate Drugs 0.000 description 1
- MMMVNAGRWOJNMW-FJBFXRHMSA-N nintedanib esylate Chemical compound CCS(O)(=O)=O.O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 MMMVNAGRWOJNMW-FJBFXRHMSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940015847 ofev Drugs 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种乙磺酸尼达尼布制剂及其应用,它是由乙磺酸尼达尼布、乳糖、微晶纤维素以及药学上可以接受的载体制备而成。可以获得流动性、稳定性、溶出度较好的乙磺酸尼达尼布制剂，从而适合工业化大生产。本发明的治疗特发性肺纤维化（IPF）的药物组合，配比合理，可以快速释放药物，对所述病症能产生很好的疗效。
Description
技术领域
本发明涉及乙磺酸尼达尼布用于制备药物的用途，尤其是用于制备适于口服的片剂和胶囊剂。
乙磺酸尼达尼布（Nintedanib esylate），分子式: C31H33N5O4·C2H6O3S，分子量: 649.76
是用于治疗特发性肺纤维化（IPF）的三类新药，目前正在进行临床前研究。
背景技术
尼达尼布（Nintedanib）是勃林格殷格翰公司开发的一种口服三联血管激酶抑制剂，2014年10月经FDA批准 OFEV® (尼达尼布) 用于治疗特发性肺纤维化 (IPF)，成为首个获准用于治疗IPF的 酪氨酸激酶抑制剂 (TKI) 。尼达尼布（Nintedanib）针对已被证实在肺纤维化病理机制中具有潜在影响的生长因子受体发挥作用，其中最为重要的就是血小板源性生长因子受体（PDGFR）、成纤维细胞生长因子受体（FGFR）和血管内皮生长因子受体（VEGFR）。通过阻断这些参与纤维化进程的信号转导通路，尼达尼布（Nintedanib）能够通过减少肺功能下降速度、从而减缓IPF疾病进展。特发性肺纤维化是一种病因不明，以肺部的进行性纤维化损害为特征的慢性进展性疾病，是最为常见的特发性间质性肺炎 。目前尚无预防方法或除肺移植外国际公认的有确切疗效的治疗方法。该在全球范围的患病率达到14-43例/每100000人。据此估算我国现有的特发性肺纤维化患者在60万人左右。2014年6月EMA宣布尼达尼布（Nintedanib）治疗特发性肺纤维化（IPF）的上市许可申请获得确认、并被EMA纳入加速审批名单。9月欧盟宣布尼达尼布（Nintedanib）联合多西他赛在一线化疗之后应用于组织学诊断为腺癌的、局部晚期或转移性或局部复发性非小细胞肺癌（NSCLC）成年患者的支持性意见。公司目前还在针对尼达尼布（Nintedanib）作为癌症治疗选择开展临床研发工作，包括非小细胞肺癌、卵巢癌、结直肠癌和肝细胞肝癌。
发明内容
本发明涉及含有乙磺酸尼达尼布的药物组合物及这类组合物用于安全有效治疗特发性肺纤维化（IPF）的应用。
本发明还涉及含有乙磺酸尼达尼布与其他药物活性物质的口服给药的药物组合物。该组合物是通过使药物活性物质的颗粒粘着在载体基质的表面获得的。使药物活性物质沉着在载体基质上的方法是为了使活性物质/载体基质颗粒的聚集降低到最少。
本发明涉及含有约50mg--300 mg乙磺酸尼达尼布的药物组合物，该组合物每日给药三次用于治疗特发性肺纤维化（IPF）优选的药物组合物含有约50mg--250 mg的乙磺酸尼达尼布，最优选的药物组合物含有约100mg--200 mg的乙磺酸尼达尼布。并且，这类优选的和最优选的药物组合物每日给药三次用于治疗特发性肺纤维化（IPF）。
用于每日给药的上述乙磺酸尼达尼布药物组合物还可不太经常性的对某些患者给药。例如，对通过每日服用乙磺酸尼达尼布药物组合物进行治疗而使他们的上呼吸道感染，急性支气管炎，肺炎及肺结核，肺癌，慢性支气管炎的镇咳得到控制的患者可施行维持治疗方案以使其免受进一步的感染。这种维持治疗方案包括每日不足一次的服用乙磺酸尼达尼布药物组合物。例如，每三或四天给药一次就足矣。
本发明的乙磺酸尼达尼布药物组合物可配制成经任何适当途径给药的形式，例如优选的口服给药组合可以是片剂、胶囊、颗粒或粉末形式。按照本领域熟知的方法，乙磺酸尼达尼布药物组合物还可以配制成非胃肠、直肠或经鼻腔给药的形式。这类制剂可包括可药用赋形剂，所述赋形剂包括这类组合物中常用的填充剂、助流剂、润滑剂、崩解剂、粘合剂等。本发明还包括缓释制剂。
含有约50mg—250mg乙磺酸尼达尼布的片剂和胶囊制剂可按照下述方法进行制备，以确保产品的高效力和良好的均匀性。首先将乙磺酸尼达尼布沉着到载体基质的表面上来制备组合物。该步骤通过下列操作完成：形成乙磺酸尼达尼布和粘合性物质的溶液，然后在载体基质颗粒保持运动的同时以喷雾的方式应用该溶液。控制条件以使颗粒的聚集降到最低。
干燥后将颗粒与组合物中包含的任何其他成分，例如崩解剂/助流剂/润滑剂混合。然后将得到的粉末压成片或填充到胶囊。
上述方法中的优选溶剂是水或不同浓度的乙醇。
粘合性物质优选是具有高稠度的聚合物。适合的物质包括聚维酮、甲基纤维素、羟甲基纤维素、羟丙甲基纤维素、羟丙基纤维素、羟乙基纤维素，聚维酮、羟甲基纤维素是优选的。终组合物中粘合性物质的含量优选为组合物总重的约1%--约10%（重量）。
终组合物中包括的崩解剂含量优选为组合物总重的约1%--7%。适合的崩解剂包括交联聚维酮、交联羧甲基纤维素、低取代羟丙甲纤维素、淀粉乙醇酸钠、预胶化淀粉和玉米淀粉，交联聚维酮是优选的。
终组合物中包括的润滑剂含量优选为组合物总重的约1%--5%。适合的润滑剂包括微粉硅胶、硬脂酸镁、硬脂酸、硬脂基富马酸钠和月桂基硫酸钠，微粉硅胶、硬脂酸镁是优选的。
具体实施方式
下列实施例说明本发明的乙磺酸尼达尼布组合物
实施例1
采用上述方法制备50毫克乙磺酸尼达尼布胶囊
| 成分 | 量%（重量/重量） | 量/粒 |
| 乙磺酸尼达尼布 | 20.00 | 50mg |
| 微晶纤维素 | 37.60 | 94 mg |
| 乳糖 | 28.00 | 70 mg |
| 聚维酮 | 4.00 | 10 mg |
| 低取代羟丙甲纤维素 | 8.00 | 20.0mg |
| 硬脂酸镁 | 0.80 | 2.0mg |
| 二氧化硅 | 1.6 | 4.0 mg |
| 纯化水 | 适量 | 适量 |
| 总计 | 100.00 | 250.00 mg |
实施例2
采用上述方法制备100毫克乙磺酸尼达尼布胶囊
| 成分 | 量%（重量/重量） | 量/粒 |
| 乙磺酸尼达尼布 | 27.60 | 100 mg |
| 微晶纤维素 | 27.60 | 100 mg |
| 乳糖 | 41.44 | 150 mg |
| 聚维酮 | 8.29 | 30mg |
| 交联聚维酮 | 8.29 | 30mg |
| 二氧化硅 | 0.55 | 2.00mg |
| 纯化水 | 适量 | 适量 |
| 总计 | 100.00 | 362.00 mg |
实施例3
采用上述方法制备150毫克乙磺酸尼达尼布胶囊
| 成分 | 量%（重量/重量） | 量/枚 |
| 乙磺酸尼达尼布 | 25.50 | 150 mg |
| 微晶纤维素 | 25.50 | 50 mg |
| 乳糖 | 38.30 | 150 mg |
| 聚维酮 | 2.50 | 10 mg |
| 交联聚维酮 | 5.00 | 20 mg |
| 低取代羟丙甲纤维素 | 2.50 | 10 mg |
| 硬脂酸镁 | 0.4 | 1.5 mg |
| 纯化水 | 适量 | 适量 |
| 总计 | 100.00 | 391.50 mg |
实施例4
采用上述方法制备100毫克乙磺酸尼达尼布片
| 成分 | 量%（重量/重量） | 量/枚 |
| 乙磺酸尼达尼布 | 25.00 | 100 mg |
| 微晶纤维素 | 25.00 | 100 mg |
| 乳糖 | 37.50 | 150 mg |
| 聚维酮 | 2.50 | 10 mg |
| 低取代羟丙甲纤维素 | 5.00 | 20 mg |
| 硬脂酸镁 | 2.5 | 10 mg |
| 二氧化硅 | 2.5 | 10 mg |
| 纯化水 | 适量 | 适量 |
| 总计 | 100.00 | 401.50 mg |
实施例5
采用上述方法制备150毫克乙磺酸尼达尼布片
| 成分 | 量%（重量/重量） | 量/枚 |
| 乙磺酸尼达尼布 | 25.50 | 150 mg |
| 微晶纤维素 | 25.50 | 50 mg |
| 乳糖 | 38.30 | 150 mg |
| 聚维酮 | 2.50 | 10 mg |
| 交联聚维酮 | 5.00 | 20 mg |
| 低取代羟丙甲纤维素 | 2.50 | 10 mg |
| 硬脂酸镁 | 0.4 | 1.5 mg |
| 纯化水 | 适量 | 适量 |
| 总计 | 100.00 | 391.50 mg |
Claims (9)
1.乙磺酸尼达尼布用于制备口服给药每日3次用于治疗特发性肺纤维化（IPF），以片剂或胶囊形式的药物组合物的用途，其中所述药物组合物含有50mg—300mg的乙磺酸尼达尼布。
2.权利要求1的用途，其中所述乙磺酸尼达尼布的含量为50mg—250mg。
3.权利要求1的用途，其中所述乙磺酸尼达尼布的含量为50mg—200mg。
4.权利要求3的用途，其中所述乙磺酸尼达尼布的含量为50mg。
5.权利要求3的用途，其中所述乙磺酸尼达尼布的含量为100mg。
6.权利要求3的用途，其中所述乙磺酸尼达尼布的含量为150mg。
7.权利要求3的用途，其中所述乙磺酸尼达尼布的含量为200mg。
8.权利要求1的用途，其中的所述组合物含有一种或多种其他药物活性物质。
9.权利要求书1的用途，其中所述的填充剂选自乳糖、木糖醇、微晶纤维素、糊精、甘露醇、山梨醇、蔗糖、淀粉、预胶化淀粉、葡萄糖、磷酸钙、磷酸氢钙、碳酸钙，及其混合物，并且所述乙磺酸尼达尼布是通过具有足够黏性的聚合黏性物质黏着在所述填充剂上的。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610406068.9A CN105902507A (zh) | 2016-06-12 | 2016-06-12 | 一种乙磺酸尼达尼布制剂及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610406068.9A CN105902507A (zh) | 2016-06-12 | 2016-06-12 | 一种乙磺酸尼达尼布制剂及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105902507A true CN105902507A (zh) | 2016-08-31 |
Family
ID=56750849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610406068.9A Pending CN105902507A (zh) | 2016-06-12 | 2016-06-12 | 一种乙磺酸尼达尼布制剂及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105902507A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108144069A (zh) * | 2016-12-02 | 2018-06-12 | 广东东阳光药业有限公司 | 一种尼达尼布包合物、制剂及其制备方法 |
| CN111848490A (zh) * | 2020-08-24 | 2020-10-30 | 江西国药有限责任公司 | 一种高纯度乙磺酸尼达尼布的制备方法 |
| CN113116904A (zh) * | 2021-03-23 | 2021-07-16 | 深圳市泰力生物医药有限公司 | 尼达尼布-甘草次酸复方制剂和药物复方制剂及在制备治疗肺纤维化药物中的应用 |
| CN114732818A (zh) * | 2022-04-29 | 2022-07-12 | 首都医科大学附属北京胸科医院 | 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104844499A (zh) * | 2015-06-05 | 2015-08-19 | 北京康立生医药技术开发有限公司 | 一锅法制备尼达尼布的合成方法 |
| CN105001143A (zh) * | 2015-07-24 | 2015-10-28 | 南京正大天晴制药有限公司 | 一种制备高纯度乙磺酸尼达尼布的方法 |
-
2016
- 2016-06-12 CN CN201610406068.9A patent/CN105902507A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104844499A (zh) * | 2015-06-05 | 2015-08-19 | 北京康立生医药技术开发有限公司 | 一锅法制备尼达尼布的合成方法 |
| CN105001143A (zh) * | 2015-07-24 | 2015-10-28 | 南京正大天晴制药有限公司 | 一种制备高纯度乙磺酸尼达尼布的方法 |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108144069A (zh) * | 2016-12-02 | 2018-06-12 | 广东东阳光药业有限公司 | 一种尼达尼布包合物、制剂及其制备方法 |
| CN108144069B (zh) * | 2016-12-02 | 2024-02-23 | 广东东阳光药业股份有限公司 | 一种尼达尼布包合物、制剂及其制备方法 |
| CN111848490A (zh) * | 2020-08-24 | 2020-10-30 | 江西国药有限责任公司 | 一种高纯度乙磺酸尼达尼布的制备方法 |
| CN113116904A (zh) * | 2021-03-23 | 2021-07-16 | 深圳市泰力生物医药有限公司 | 尼达尼布-甘草次酸复方制剂和药物复方制剂及在制备治疗肺纤维化药物中的应用 |
| CN113116904B (zh) * | 2021-03-23 | 2022-11-29 | 深圳市泰力生物医药有限公司 | 尼达尼布-甘草次酸复方制剂和药物复方制剂及在制备治疗肺纤维化药物中的应用 |
| CN114732818A (zh) * | 2022-04-29 | 2022-07-12 | 首都医科大学附属北京胸科医院 | 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用 |
| WO2023207398A1 (zh) * | 2022-04-29 | 2023-11-02 | 首都医科大学附属北京胸科医院 | 一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015185013A1 (zh) | 包含喹啉衍生物或其盐的药物组合物及其制备方法 | |
| JP2012518008A (ja) | 非晶質ｃｄｄｏ−ｍｅを含有する遅延放出性経口投薬組成物 | |
| CN105902507A (zh) | 一种乙磺酸尼达尼布制剂及其应用 | |
| CN109908145B (zh) | 防己诺林-7-丙酸酯与酪氨酸激酶抑制剂的药物组合物 | |
| CN105919955A (zh) | 一种鲁索利替尼制剂及其应用 | |
| CN104042577A (zh) | 一种稳定的托匹司他片及其制备方法 | |
| CN101747305B (zh) | 硝克柳胺化合物晶v型、其制法和其药物组合物与用途 | |
| CN107913256A (zh) | 一种治疗肺动脉高压的马西替坦口腔崩解片及其制备方法 | |
| CN106074431A (zh) | 一种富马酸沃诺拉赞制剂及其应用 | |
| CN106074409A (zh) | 一种奥拉帕尼制剂及其应用 | |
| CN105902506A (zh) | 一种沙卡布曲缬沙坦制剂及其应用 | |
| CN105963268A (zh) | 一种乙磺酸尼达尼布分散片及其制备方法 | |
| CN104013589A (zh) | 一种阿西替尼口腔崩解片及其制备方法 | |
| RU2414903C1 (ru) | Фармацевтический состав пролонгированного действия на основе клозапина перорального введения | |
| CN101265275A (zh) | 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯 | |
| TWI738729B (zh) | 一種含有吡咯并六員雜環化合物或其可藥用鹽的藥物組成物的製備方法 | |
| CN115400099A (zh) | 卡利拉嗪口溶膜组合物、其制备方法及应用 | |
| WO2019230937A1 (ja) | 溶出性に優れた経口固形製剤 | |
| CN109875999B (zh) | 泊那替尼在kit突变型恶性黑色素瘤中的应用 | |
| TWI750152B (zh) | 一種含有吡咯并六員雜環化合物或其可藥用鹽的藥物組成物 | |
| CN101385718B (zh) | 一种治疗高血脂症的渗透泵制剂组合物 | |
| CN103550182A (zh) | 一种肠溶缓释组合物 | |
| CN104434850B (zh) | 一种含有阿德福韦酯的口服固体药物组合物 | |
| CN105748422B (zh) | 包含依那普利和非洛地平的药物组合物 | |
| CN106176659B (zh) | 一种坦度螺酮肠溶片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160831 |
|
| WD01 | Invention patent application deemed withdrawn after publication |